Related references
Note: Only part of the references are listed.Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
William D. Travis
MODERN PATHOLOGY (2012)
Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands
Lola Fernandez-Messina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
Kui Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B
Annette Paschen et al.
CLINICAL CANCER RESEARCH (2009)
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus
Zhenpeng Dai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions
Naela A. Arreygue-Garcia et al.
BMC CANCER (2008)
Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma
Keisuke Kohga et al.
CANCER SCIENCE (2008)
NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells
K. Kraetzel et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Soluble NKG2D ligands: prevalence, release, and functional impact
Helmut Rainer Salih
Frontiers in Bioscience-Landmark (2008)
Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients
Shigehiro Tamaki et al.
HUMAN IMMUNOLOGY (2008)
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Beatrice Le Maux Chansac et al.
INTERNATIONAL IMMUNOLOGY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
NKG2D ligands expression and NKG2D-Mediated cytotoxicity in human laryngeal squamous carcinoma cells
X. M. Chen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2008)
NKG2D ligands:: key targets of the immune response
Segundo Gonzalez et al.
TRENDS IN IMMUNOLOGY (2008)
Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B
Tetsuro Baba et al.
CANCER SCIENCE (2007)
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Brett K. Kaiser et al.
NATURE (2007)
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
Vera Rebmann et al.
CLINICAL IMMUNOLOGY (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
Stefan Holdenrieder et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity
Angela Maerten et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
NKG2D ligands are expressed on stressed human airway epithelial cells
Michael T. Borchers et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity
Veronika Groh et al.
NATURE IMMUNOLOGY (2006)
The NKG2D-activating receptor mediates pulmonary clearance of Pseudomonas aeruginosa
MT Borchers et al.
INFECTION AND IMMUNITY (2006)
Proteolytic release of soluble UL16-binding protein 2 from tumor cells
I Waldhauer et al.
CANCER RESEARCH (2006)
Release of MICB molecules by tumor cells: Mechanism and soluble MICB in sera of cancer patients
Helmut Rainer Salih et al.
HUMAN IMMUNOLOGY (2006)
Soluble MICA in malignant diseases
S Holdenrieder et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression
Hyunkeun Song et al.
CELLULAR IMMUNOLOGY (2006)
Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas
M Jinushi et al.
JOURNAL OF HEPATOLOGY (2005)
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma
L Raffaghello et al.
NEOPLASIA (2004)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity
C Maccalli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity
C Dunn et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
New aspects of natural-killer-cell surveillance and therapy of cancer
MJ Smyth et al.
NATURE REVIEWS CANCER (2002)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines
K Dohmoto et al.
LUNG CANCER (2000)
Share Paper
